Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC5R | P33032 | 10/20 | 0.50 |
| ▸ | MC4R | P32245 | 6/20 | 0.50 |
| ▸ | MC3R | P41968 | 6/20 | 0.50 |
| ▸ | NAMPT | P43490 | 8/20 | 0.42 |
| ▸ | MC1R | Q01726 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4050134 | 1.00 | MC5R (0.50) | MC5RMC4RMC3RNAMPTMC1R | |
| SCHEMBL4050137 | 1.00 | MC5R (0.50) | MC5RMC4RMC3RNAMPTMC1R | |
| SCHEMBL13068821 | 0.93 | MC5R (0.52) | MC5RMC4RMC3RNAMPTMC1R | |
| SCHEMBL18433159 | 0.93 | MC5R (0.52) | MC5RMC4RMC3RNAMPTMC1R | |
| SCHEMBL4049534 | 0.93 | MC5R (0.52) | MC5RMC4RMC3RNAMPTMC1R | |
| SCHEMBL4049528 | 0.93 | MC5R (0.52) | MC5RMC4RMC3RNAMPTMC1R | |
| SCHEMBL14627481 | 0.93 | MC5R (0.52) | MC5RMC4RMC3RNAMPTMC1R | |
| SCHEMBL14541435 | 0.93 | MC5R (0.52) | MC5RMC4RMC3RNAMPTMC1R | |
| SCHEMBL2669494 | 0.93 | MC5R (0.52) | MC5RMC4RMC3RNAMPTMC1R | |
| SCHEMBL4049536 | 0.93 | MC5R (0.52) | MC5RMC4RMC3RNAMPTMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1409468-B9 | GUANIDINOBENZAMIDES AS MC4-R AGONISTS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-1409468-B1 | GUANIDINOBENZAMIDES AS MC4-R AGONISTS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20070004743-A1 | Intranasal administration of mc4-r agonists | HEALTHPARTNERS RESEARCH FOUNDATION | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004743-A1 | Intranasal administration of mc4-r agonists | MC4R, MC5R, MC3R | MC5R 2/4885MC4R 1/4885MC3R 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.